Dupilumab

證據等級: L5

預測適應症: 10 個

Dupilumab: From Atopic Dermatitis to Bronchitis

One-Sentence Summary

Dupilumab is a human monoclonal antibody targeting IL-4Rα that blocks IL-4/IL-13 signaling; per the evidence captured in this dataset, it has established use in Th2-driven inflammatory diseases such as atopic dermatitis, asthma, and eosinophilic COPD. The TxGNN model predicts it may also be effective for Bronchitis, but this is currently supported by only 1 clinical trial (with a disease-label mismatch flag) and 6 publications, most of which actually address asthma or COPD rather than bronchitis specifically.

Quick Overview

Item	Content
Original Indication	Not recorded in this dataset (no Finland marketing licenses on file); literature evidence in this pack indicates the drug is approved for atopic dermatitis, asthma, and eosinophilic COPD
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.92% (rank 1226)
Evidence Level	L3
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured drug record (original_moa: [Data Gap]). Based on information embedded in the supporting literature, dupilumab is a fully human IgG4 monoclonal antibody that binds the shared IL-4Rα subunit, blocking downstream signaling of interleukin-4 and interleukin-13 — the key cytokines driving Th2/type-2 airway and skin inflammation. Its efficacy in Th2-driven diseases (atopic dermatitis, moderate-to-severe asthma, eosinophilic COPD) is well documented in the evidence pack.

Bronchitis — particularly chronic or eosinophilic bronchitis — can share the same Th2/eosinophilic inflammatory pathway seen in asthma and COPD exacerbations, which is the mechanistic basis for the TxGNN prediction. However, "bronchitis" as a standalone diagnostic label is broader and less specific than asthma or COPD, and the trial/literature evidence retrieved for this indication is largely borrowed from adjacent, better-studied conditions rather than bronchitis itself.

Critically, the single retrieved clinical trial (NCT04362501) was graded C (data mismatch) by the relevance review — its actual target population is chronic rhinosinusitis without nasal polyps (CRSsNP), not bronchitis, sharing only the underlying Th2 mechanism. This means the mechanistic rationale is plausible, but direct, disease-specific clinical evidence for bronchitis is currently lacking.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04362501	Phase 2	Completed	33	Randomized, double-blind, placebo-controlled study of dupilumab for chronic rhinosinusitis without nasal polyps (CRSsNP) — relevance grade C: actual target disease is CRSsNP, not bronchitis; only shares Th2 inflammatory mechanism, flagged as a data-label mismatch

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34597534	2022	RCT extension (TRAVERSE)	Lancet Respir Med	Long-term (>1 year) open-label extension confirming safety and sustained efficacy of dupilumab in moderate-to-severe asthma, not bronchitis specifically
32428511	2020	RCT substudy (imaging)	Chest	MRI-based ventilation defect imaging in prednisone-dependent severe asthma patients on anti-T2 biologic treatment
30273510	2019	Systematic Review/Meta-analysis	J Asthma	Meta-analysis of RCTs evaluating dupilumab efficacy/safety in uncontrolled asthma
39904363	2025	Review (COPD)	Tuberc Respir Dis	Comprehensive review of pharmacologic therapies (including biologics) for preventing COPD exacerbations
30196731	2018	Review	Expert Opin Pharmacother	Discusses treatment challenges in smoking-induced airway diseases including chronic bronchitis, emphysema, and asthma-COPD overlap; notes these patients are typically excluded from major trials
38488768	2024	Review (pediatric plastic bronchitis)	Pediatr Pulmonol	Reviews novel therapies for eosinophilic pediatric plastic bronchitis (abstract not available in this dataset)

Finland Market Information

No Finland marketing authorizations are on file for dupilumab in this dataset — market_status: 未上市 (Not Marketed), total_licenses: 0.

Safety Considerations

Please refer to the package insert for safety information.

Note: A Blocking-severity data gap (DG001 — TFDA/Fimea package insert warnings and contraindications) is recorded in this dataset, which by itself prevents entry into the S1 safety pre-assessment stage regardless of efficacy evidence strength.

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence specific to bronchitis is weak: the sole clinical trial is a confirmed disease-label mismatch (actual target: CRSsNP), and the literature predominantly covers asthma and COPD rather than bronchitis itself.
A Blocking-severity data gap (missing package insert warnings/contraindications) prevents even initial safety screening (S1), independent of the efficacy question.

To proceed, the following is needed:

Retrieve TFDA/Fimea package insert (warnings, contraindications) to unblock S1 safety review (DG001)
Confirm mechanism of action via DrugBank API query (DG002)
Source bronchitis-specific (not asthma/COPD-proxy) clinical trial and literature evidence, or formally re-scope the indication to a better-defined Th2-driven phenotype (e.g., eosinophilic/chronic bronchitis)
Separately, note that rank-2 predicted indication dermatitis in this same dataset carries substantially stronger evidence (L1, multiple completed Phase 3/4 RCTs, "Proceed with Guardrails") and may warrant prioritized evaluation ahead of bronchitis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.